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Background. Ciprofloxacin is used as antimicrobial prophylaxis in pediatric acute lymphoblastic leukemia (ALL) to decrease 
infections with gram-negative bacteria. However, there are no clear guidelines concerning prophylactic dose.
Aims. To determine the pharmacokinetics and pharmacodynamics (PKPD) of ciprofloxacin prophylaxis in a pediatric ALL 
population. The effect of patient characteristics and antileukemic treatment on ciprofloxacin exposure, the area under the con-
centration time curve over minimal inhibitory concentration (AUC24/MIC) ratios, and emergence of resistance were studied.
Methods. A total of 615 samples from 129 children (0–18 years) with ALL were collected in a multicenter prospective study. 
A population pharmacokinetic model was developed. Microbiological cultures were collected prior to and during prophylaxis. An 
AUC24/MIC of ≥125 was defined as target ratio.
Results. A 1-compartment model with zero-order absorption and allometric scaling best described the data. No significant 
(P < .01) covariates remained after backward elimination and no effect of asparaginase or azoles were found. Ciprofloxacin AUC24 
was 16.9 mg*h/L in the prednisone prophase versus 29.3 mg*h/L with concomitant chemotherapy. Overall, 100%, 81%, and 18% of 
patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125. In 13% of the patients, resistant bacteria 
were found during prophylactic treatment.
Conclusion. Ciprofloxacin exposure shows an almost 2-fold change throughout the treatment of pediatric ALL. Depending on 
the appropriateness of 125 as target ratio, therapeutic drug monitoring or dose adjustments might be indicated for less susceptible 
bacteria starting from ≥ 0.125 mg/L to prevent the emergence of resistance and reach required targets for efficacy.
Keywords.  acute lymphoblastic leukemia; pharmacokinetics; ciprofloxacin; minimal inhibitory concentration; pediatrics.
During the treatment of hematological malignancies, patients 
may receive antimicrobial prophylaxis to suppress gram-negative 
bacterial colonization and prevent infection in this immunosup-
pressed population [1]. Studies have shown the effectiveness of 
antimicrobial prophylaxis in pediatric acute leukemia and supe-
riority of quinolones over other antibiotics [2–4]. However, there 
is no guideline concerning the prophylactic dose of antibiotics. 
Hence, in most situations therapeutic dose-levels are used [5, 
6]. In contrast to beta-lactam antibiotics, quinolones have a fast 
and concentration-dependent killing with a more sustained 
postantibiotic effect against most gram-negative pathogens [7, 
8]. Therefore, the area under the concentration time curve over 
the minimal inhibitory concentration (AUC24/MIC) is used as 
pharmacodynamics/pharmacokinetics (PKPD) target for quin-
olones [6, 7, 9]. Studies showed higher probabilities of clinical 
and microbiologic cure rates with AUC24/MIC  >  125 [6, 7]. 
However, it also showed that AUC24/MIC of >125 might not be 
achieved in all patients, especially with less susceptible bacteria 
[7, 9–11]. Emergence of resistance is another area of concern, es-
pecially in our patients receiving antibiotics for an extended pe-
riod. De novo resistance develops in a gradual, stepwise manner, 
usually from the accumulation of mutations.
In this study the pharmacokinetics and pharmacodynamics 
of ciprofloxacin were evaluated in a large pediatric ALL popula-
tion to determine the effects of patient characteristics and treat-
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of gram-negative bacteria and susceptibility to ciprofloxacin 
was evaluated. Subsequently, Monte Carlo simulations were 
performed to evaluate dosing regimens and MIC values in rela-
tion to AUC24/MIC ratios.
MATERIALS AND METHODS
Patients and Treatment
The study was designed as a prospective multicenter Dutch 
Childhood Oncology Group (DCOG) study performed in the 
7 pediatric oncology centers in the Netherlands. Children aged 
0–18 years with ALL were eligible for the study when treated 
according to the DCOG ALL-11 protocol (April 1, 2012—on-
going), or the Interfant-06 protocol (February 2006—August 
2016), receiving ciprofloxacin as antimicrobial prophylaxis in a 
dose of 15 mg/kg twice daily (maximum 1000 mg/day). Patients 
with Down syndrome were excluded from the study due to pos-
sible altered pharmacokinetics [12–14]. One infant was treated 
according to the Interfant-06 protocol with samples in week 
1 containing prednisolone. The DCOG ALL-11 and DCOG 
Interfant-06 protocols were institutional review board (IRB) ap-
proved (EudraCT: 2012–00006725 (ALL-11) & 2005–004599-
19 (Interfant-06); Dutch Trial Registry nr. 3379).
Sample Collection and Analysis
For the PK analysis, ciprofloxacin steady state samples were col-
lected between February 2012 and August 2016. Samples were 
collected >24 hours after first administration and following 
a single dose (trough, t = 1, t = 2, and t = 4 hours). Samples 
were collected during 3 treatment phases; week 1 [block A], 
52 days after start treatment [block B], and additional trough 
samples between block A  and B and during risk-group (me-
dium risk group [MRG]) intensification phase [block C]. In 
block A, patients received prednisolone and during block B 
and C concomitant chemotherapy (Figure 1 and supplement). 
Samples were analyzed with liquid chromatography tandem 
mass spectrometry (LC-MS/MS) at the department of Hospital 
Pharmacy in the Academic University Medical Centers in 
Amsterdam, The Netherlands. (LC: Shimadzu LC-30 Nexera 
[Nishinokyo-Kuwabaracho, Japan]; MS: AB Sciex 5500 QTrap® 
[Framingham, MA, USA]; high-performance liquid chro-
matography column: Thermo ScientificTM Hypersil GoldTM 
50  ×  2.1  mm, 1.9  μm [Waltham, MA, USA]). Blood samples 
were collected in K2 EDTA tubes and centrifuged at room tem-
perature within 2 hours after withdrawal. Supernatant (serum) 
was collected and stored at −80° Celsius prior to analysis.
Microbiology
Routine surveillance cultures were taken according to DCOG 
supportive care guidelines prior to start prophylaxis and during 
treatment. Rectal and throat swabs were collected during periods 
of intense chemotherapy either weekly (when hospitalized) or 
every 2–3 weeks (outpatient clinic), including additional patients 
treated according to the ALL-11 protocol (outside of PK-study). 
Ciprofloxacin susceptibility was tested with VITEK®-2 system 
(BioMérieux, Marcy-l’Étoile, France) at the department of 
Microbiology in the Erasmus MC, Rotterdam, The Netherlands. 
Results were presented as MIC ≤ 0.25, 0.5, 1 and > 2 mg/L (MIC 
>0.5 mg/L is considered resistant) [15]. The incidence of febrile 
neutropenia during treatment was evaluated using reported epi-
sodes of febrile neutropenia to the DCOG. Febrile neutropenia 
was defined as neutrophil count <1.0*109 L−1 with a single tem-
perature of >38.3○ Celsius or ≥38.0○ Celsius an hour apart.
Pharmacokinetic Analysis
The total concentration time profiles of ciprofloxacin were 
analyzed using the nonlinear effects modeling approach im-
plemented in nonlinear mixed effects modeling (NONMEM®) 
first-order conditional estimates (FOCE) with interaction (ver-
sion 7.3; Globomax LLC, Ellicott City, MD, USA]). The data 
were initially fitted to a 1-compartment linear model with 
first-order absorption followed by more complex models. 
Figure 1. Treatment phases and sampling schedule. Overview of the treatment blocks and samples. T1, T2, and T4 are, respectively, 1, 2, and 4 hours after last administra-
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Improvement of the fit of the model was evaluated quantita-
tively by the precision of the estimated PK parameters and the 
change in the objective function values (OFV), and visually by 
goodness-of-fit plots (GoF) and visual predictive checks (VPC). 
A priori the parameters were normalized to a weight of 70 kil-
ogram (kg) and allometrically scaled, with an exponent of 0.75 
for clearance (CL) and 1 for apparent volume of distribution 
(V). A 3.84-point decrease in OFV for 1 degree of freedom was 
considered a significant improvement with a P-value of <.05. 
The evaluation of covariates was done through stepwise regres-
sion with iterative forward selection (P  <  .05) and backward 
elimination (P < .01) [16]. Continuous covariates were centered 
around the median. A  proportional error model was used to 
describe the residual error in plasma concentrations. The ro-
bustness of the estimated model parameters was evaluated 
by a nonparametric bootstrap procedure (n = 1000). A visual 
predictive check was performed for internal validation of the 
model. Monte Carlo simulations were performed with the final 
model (n = 1000) for patients with body weights of 10–100 kg, 
and ciprofloxacin dose of 15 mg/kg with a maximum of 500 mg 
during treatment phases block A, B, and C.  The area under 
the curve (AUC) was calculated for the different patients and 
dosages.
Statistical Analysis
The patient characteristics height, weight, age, albumin, 
creatinine, aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT), bilirubin, and urea for different 
treatment phases were compared using 2-sided Mann-Whitney 
U test with α = 0.05. The Pearson χ 2 test was used to compare 
sex, pharmaceutical formulation (tablet, capsule or oral liquid) 
and administration route (oral or via tube).
RESULTS
Patients and Samples
A total of 134 patients were enrolled in the study between 
October 2012 and August 2016. Five patients were excluded 
due to missing data. A total of 129 patients were included for 
the PK analysis; 646 samples were available for analysis. And 31 
samples (4.8%) were excluded from the analysis, due to missing 
sampling data (n  =  2; 0.3%), technical issues (eg, <250 uL 
plasma, n = 7; 1.1%), <lower limit of quantification of 0.02 mg/L 
(n = 10; 1.5%), or unrealistic concentrations due to sampling 
artifacts (n = 12; 2.0%). A  total of 615 samples were used for 
the PK analysis. A detailed description of patient characteristics 
and samples is shown in Table 1. Observed differences between 
patients in treatment phases (mean [interquartile range]) were, 
albumin (38 [34–40] vs 33 [26–37] g/L; P < .001) and bilirubin 
(12 [6–14] vs 17 [9–18] umol/L; P = .02) for, respectively, block 
A versus B; urea (4.9 [3.8–6.2] vs 6.4 [4.5–7.3] mmol/L; P = .02) 
for block A  versus C; and ASAT (57 [31–54] vs 55 [24–43] 
U/L; P = .03) and urea (4.8 [3.5–5.0] vs 6.4 [4.5–7.3] mmol/L; 
P < .001) for block B versus C.
Pharmacokinetic Model
Initially a 1-compartment model with first-order absorption 
was evaluated. The samples were a priori stratified in 3 treat-
ment periods (block A, B, and C) and associated with CL and 
V. Compared to block A, CL and V were, respectively, 44% and 
49% lower in block B and 31% and 33% lower in block C (de-
crease of 157 points in OFV; P < .0001). The association between 
treatment blocks and PK parameters greatly influenced the sta-
bility of the model and was therefore included in the structural 
model. Addition of a peripheral compartment model decreased 
Table 1. Patient Characteristics








Patients (n) 129 91 a 76a 74a
Age (y) 5.6 (0.3–17.7) 5.6 (1.2–17.7) 5.0 (0.3–17.0) 6.2 (1.4–17.7)
Weight (kg) 21 (9–86) 20 (10–79) 21.5 (9–72) 25 (10–86)
Height (cm) 120 (78–190) 116 (81–188) 120 (78–184) 126 (79–190)
Female:male 39% vs 61% 38% vs 62% 39% vs 61% 39% vs 61%
Creatinine (umol/L) 28 (8–67) 28 (8–67) 28 (10–63) 28 (12–63)
GFR (ml/min/1.73 m2) 179 (80–494) 162 (94–494) 181 (80–348) 176 (80–340)
ASAT (U/L) 37 (13–551) 37 (13–551) 37 (13–513) 37 (10–513)
ALAT (U/L) 62 (8–1321) 62 (8–1321) 62 (13–1321) 62 (13–1321)
Bilirubin (umol/L) 9 (2–158) 9 (2–64) 10 (2–158) 9 (2–64)
Urea (mmol/L) 4.5 (0.8–33) 4.5 (0.8–11.6) 4.5 (0.8–33) 4.9 (0.8–40)
Albumin (g/L) 37 (13–100) 37 (21–100) 36 (13–47) 37 (21–100)
Samples (n) 615 323 204 88
Samples per patient (n) 4 (1–13) 4 (1–13) 3 (1–4) 1 (1–3)
Dose ciprofloxacin (mg) 300 (75–500) 300 (75–500) 300 (75–500) 343 (80–500)
Azoles (%) 51% 3% 63% 38%
Abbreviations: ALAT, alanine aminotransferase; ALL, acute lymphoblastic leukemia; ASAT, aspartate aminotransferase; GFR, glomerular filtration rate.
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the OFV of 19.2 points (P <  .01). However, the parameters of 
the second compartment could not be estimated precisely and 
resulted in a less stable model.
Different absorption models were evaluated; first-order 
absorption, zero-order absorption, lag time, and multi-
compartment absorption models (up to 20 transit compart-
ments). The absorption phase was best described with a 
zero-order absorption model. The final structural model was 
a 1-compartment model with zero-order absorption with allo-
metric scaling and the association between treatment phase and 
CL and V.  This model was used for the subsequent covariate 
analysis.
Covariate Analysis
The covariates were tested once at the time for improvement of 
the structural model. The age adjusted GFR decreased the OFV 
with 5.3 points (P < .05), bilirubin resulted in a 4.1-point decrease 
in OFV (P < .05), and ASAT with 4.8 points (P < .05). Although 
inter-individual variability on absorption rate (D) could not 
be adequately assessed, the covariate age could, and decreased 
the OFV with 5.7 points (P < .05). Age showed an exponential 
correlation with absorption rate, with increasing age resulting 
in extended time in the gut. The other covariates height, body 
surface area (BSA), sex, ALAT, albumin, and treatment center 
did not significantly improve the base model (P > .05). CL and 
exposure of patients (n = 14) who developed resistant micro-
organisms during prophylaxis (MIC ≥ 0.5 mg/L) did not differ 
significantly from patients without (2.1-point decrease in OFV; 
P > .05). Neither pharmaceutical form nor administration route 
showed a significant effect. The covariates with a significant im-
provement were implemented in the PK model. However, none 
of the covariates were included in the final model after the more 
stringent backward elimination (P < .01).
The concomitant use of azoles was different between the 
blocks, whereas 3% of the patients received azoles in block A, 
63% did in block B, and 38% in block C. Azoles as covariate did 
not improve the model with a decrease in OFV of .12 points. 
Additionally, concomitant use of asparaginase was evaluated in 
a subset of patients (n = 74) within block B and did not show a 
significant difference with a decrease of .53 points in OFV. The 
other chemotherapeutic drugs were received by all patients and 
could therefore not be compared within a single block.
The final model was a 1-compartment model with zero-order 
absorption with allometric scaling, an association between 
treatment phase and CL and V. The parameter estimates of the 
final model for block A were: CL 86 L/h/70 kg, V 695 L/70 kg. CL 
was reduced by 44% and 32%, and V was reduced by 49% and 
34% in, respectively, block B and C compared to block A. The 
inter-individual variability was 27% for CL and 41% for V. For 
detailed PK estimates refer to Table 2. The ciprofloxacin protein 
binding showed a weak linear correlation over the concentra-
tion range with a coefficient of 0.16 (P <  .001) (Suppl. Figure 
A). The median percentage of unbound ciprofloxacin was 63%. 
The AUC24 and unbound AUC24 (fAUC24) are shown in Table 3. 
A steep decline was observed in patients achieving AUC24/MIC 
ratios of ≥125 for MIC values of ≥0.25 mg/L, which was espe-
cially low in block A and C with, respectively, 1% and 18% of 
the patients (Table 3).
Model Validation
The nonparametric bootstrap procedure was performed to test 
the robustness of the model. A total 916 of the 1000 runs were 
successful. The results are shown in Table 2. The estimates of 
the final model are in accordance with the results from the 1000 
bootstrap replicates. The plot of the prediction corrected visual 
predictive check shows the median and 90% confidence interval 
of the observed ciprofloxacin concentrations (Figure  2). The 
Table 2. PK Parameters and Bootstrap
Parameter
NONMEM Bootstrap
Estimate RSE (%) 95% CI (lower) 95% CI (upper) Shrink. (%) Median 95% CI (lower) 95% CI (upper)
ΘCL/F (L/h/70 kg) 86 5.5 76.6 95.0 ... 88 79.1 97.4
ΘV/F (L/70 kg) 695 8.9 574 816 ... 692 594 821
ΘCL block B 0.56 6.5 .49 .63 ... 0.58 .50 .66
ΘV block B 0.51 9.1 .42 .60 ... 0.54 .44 .65
ΘCL block C 0.68 10.8 .54 .82 ... 0.68 .56 .89
ΘV block C 0.66 16.7 .44 .87 ... 0.67 .49 1.0
ΘD1 0.62 25.0 .32 .92 ... 0.65 .41 1.0
ω2CL (%) 26.6 25 19 34 22 41 29 53
ω2V (%) 39.2 17 33 48 24 50 33 67
σ2prop 0.46 4 .42 .49   7 0.40 .35 .45




prop, random effect parameter that represents 
proportional residual variance; Θ CL/F,  population estimate for clearance including bioavailability; Θ V/F, population estimate of apparent volume of distribution including bioavailability; Θ CL block, 
population estimate for differences between block A and B or C on clearance; Θ V block, population estimate for differences between block A and B or C on distribution; Θ D1, population esti-
mate absorption rate constant.
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model adequately predicts the time course of the ciprofloxacin 
plasma concentration (Figure 3).
PKPD Simulations
Monte Carlo simulations were performed to show the per-
centage of patients achieving the target AUC24/MIC of 125 
with the current dose over a range of MIC values (Figure  4). 
For the MIC values of 0.063, 0.125, 0.25, and 0.5 mg/L, respec-
tively, 90%, 37%, 1%, and 0% (block A); 100%, 86%, 27%, and 
0% (block B); and 99%, 74%, 13%, and 0% (block C) of patients 
achieved an AUC24/MIC ratio of ≥125. The AUC was lower in 
patients with high body weight compared to low body weight. 
Note that the maximum dose is 500  mg/dose; hence patients 
with body weight >33.3 kg received a relative lower dose on a 
weight basis.
Microbiology
In sum, 251 rectal and throat surveillance cultures of 121 pa-
tients were collected and analyzed (including 67 patients from 
the PK analysis). MIC values were determined in case of posi-
tive bacteremia. Ciprofloxacin resistant gram-negative bacteria 
(MIC ≥ 0.5 mg/L) were identified in routine colonization rectal 
cultures in 26 out of 121 (21%) all with MIC > 2 mg/L. In 16 out 
of 121 (13%) patients, resistant gram-negative cultures emerged 
during ciprofloxacin prophylaxis, with a median of 34  days 
(range 5–279  days) after diagnosis, in 4 (3%) patients were 
Table 3. AUC and AUC24/MIC Ratios
Overall Block A Block B Block C
Patients (n) 129 91 76 74
































% of patients AUC24/MIC ≥ 125
 Overall Block A Block B Block C
MIC 0.063 100% 97% 100% 99%
MIC 0.125 81% 65% 92% 87%
MIC 0.25 18% 1% 40% 18%
MIC 0.5 0% 0% 0% 0%
Abbreviations: AUC24, 24-hour area under the curve; MIC, minimal inhibitory concentration.
Figure 2. Visual predictive check. Visual predictive checks for each block. The fit of the predicted ciprofloxacin concentrations versus the observed concentrations of the 
final model. The predictions are in line with the observed data. The red solid line indicates the median observed concentrations and the surrounding opaque red area the 
simulation based 95% confidence interval for the median. The red dashed lines indicates the observed 5% and 95% percentiles, and the surrounding opaque blue areas show 
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colonized with resistant bacteria prior to prophylaxis. For 6 (5%) 
patients with resistant cultures, no data were available prior to 
prophylaxis and remain inconclusive. Resistance occurred 
most frequently in Escherichia coli (67%) and Pseudomonas 
aeruginosa (14%) (Table 4). A detailed overview of the cultures 
and MIC values is presented in Supplement Table A. The AUC 
of patients in block A who developed gram-negative bacteremia 
during prophylaxis (n  =  12) was lower than patients without 
(n = 54; P = .025). However, no difference in AUC was observed 
in block B, C, or overall (see Figure 5).
A total of 165 episodes of febrile neutropenia were reported 
to the DCOG in 85 of 108 patients during their ALL treatment; 
74 (45%) of these episodes (64 patients) occurred in the first 
weeks of treatment. In 71 cases microbiological documenta-
tion was available, with 7 (10%) documented gram-negative 
blood or surveillance cultures (1 blood, 5 rectal, urinary tract 
or throat, and 1 unknown). Thirty-eight of these 71 episodes 
occurred in the first weeks of treatment including 3 (8%) of the 
documented gram-negative bacteremia.
DISCUSSION
Overall, a total of 81% of the studied patients achieved an 
AUC24/MIC ratio of ≥125 for ciprofloxacin susceptible bacteria 
with MIC of ≤0.125 mg/L and 100% with MIC of ≤0.063 mg/L. 
However, the majority of patients did not achieve the target ratio 
Figure 3. Goodness-of-fit plot. Goodness-of-fit plots final model. Predicted population concentrations versus observed concentrations of the final model (upper left); 
predicted individual concentrations versus observed concentrations of the final model (upper right). Individual weighted residuals versus individual predictions (lower left), 
conditional weighted residuals versus time after dose (h = time in hours) (lower right). Abbreviation:  IWRES, iindividual weighted residuals.
Figure 4. Patients with AUC24/MIC  ≥  125 in block A, B, and C.  The effect of 
treatment phase and patient weight on exposure and AUC24/MIC ratio. Simulation 
(n = 1000) of patients with a weight of 10–100 kg and a dose of 15 mg/kg (max 
500 mg) during different treatment phases (block A, B, and C). The x-axis shows 
different MIC values in mg/L, and the y-axis shows the percentage of patients ex-
ceeding the AUC24/MIC threshold of 125. A steep decline is shown in patient ex-
ceeding the threshold ratio for MIC > 0.125 and >0.25. Abbreviation: AUC24/MIC, 
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for a MIC value of ≥0.25 mg/L (99% and 60% in, respectively, 
block A and B), which is still considered susceptible. Low rates 
above the AUC24/MIC target of 125 were also found in other 
studies for MIC values >0.25 mg/L [7, 9–11, 17]. Although the 
susceptible MIC values were classified as ≤0.25 mg/L, the exact 
MIC values are likely much lower. The EUCAST reference da-
tabase showed MIC predominantly ≤0.064 mg/L with mean of 
.015  mg/L for wild-type E.  coli [18]. At these MIC levels the 
AUC24/MIC target of 125 is reached in all patients. Patients did 
not reach target AUC24/MIC for our MIC cutoff of >2 mg/L.
The observed rate of gram-negative bacteremia throughout 
the ALL treatment in the subset of patients was 16%, compa-
rable to the study by Alexander et al (21%) in pediatric acute 
leukemia patients with levofloxacin [4]. Although higher cure 
rates have been shown above an AUC24/MIC of ≥125, it is un-
clear how this translates to prophylactic treatment. In addition 
to treatment efficacy, the emergence of resistance and specific 
surface site colonization should be considered [19]. The AUC24/
MIC should be sufficient to prevent loss in susceptibility and 
emergence of resistance. In this study a correlation was found 
between exposure in week 1 (block A) and patients who devel-
oped resistant gram-negative bacteremia during ciprofloxacin 
prophylaxis. However, the AUC24/MIC in these patients cannot 
be determined as the exact MIC value is not known.
The required AUC24/MIC has been shown to differ between 
strains and fluorquinolones [20, 21]. Felsenstein et al observed 
a significant reduction in infections caused by gram-negative 
rods but a higher proportion of gram-positive bacterial and 
fungal infection with ciprofloxacin in pediatric AML patients 
[22]. Sung et  al used levofloxacin with higher gram-positive 
sensitivity [2]. This might be something to take into account 
with regard to prophylaxis or treatment concerning gram-pos-
itive bacteremia.
This study showed an almost 2-fold change in ciprofloxacin 
clearance and exposure for different treatment phases. In the 
literature a wide range of CL can be found from 15.9 L/h/70 kg 
to 102.5 L/h/70 kg in a wide variety of pediatric patients (eg, 
severe malnutrition, cystic fibrosis), the CL and AUC in this 
study falls in the upper range [10, 23–26]. Ciprofloxacin is for 
40–50% excreted in urine and 20–35% via biliary clearance or 
transintestinal elimination [27–29]. Most patients will have re-
ceived hyperhydration and allopurinol/rasburicase (and some-
times diuretics) in week 1 to prevent tumor lysis syndrome, 
which could affect the estimation of CL. Other factors that might 
contribute to the difference in CL and AUC include kidney 
and liver function, transporters (eg, organic anion transporter 
[OAT3]), bioavailability, and drug interactions [27, 30, 31]. 
A significant effect of GFR, bilirubin, and ASAT (P < .05) was 
observed; however, it was not implemented in the final PK 
model after more stringent backward elimination (P < .01). All 
ciprofloxacin administrations were oral. Therefore, CL is the 
ratio of clearance and bioavailability, and changes in bioavaila-
bility (eg, due to binding of ciprofloxacin to multivalent cations 
in milk or tube feeding) are reflected in the CL.
The PK of ciprofloxacin was best described with a 1-compart-
ment model with zero-order absorption. Other studies have es-
tablished both 1- and 2-compartment models for ciprofloxacin 
[23, 32–34, 26]. A 2-compartment model was not supported by 
the data in our analysis with twice daily ciprofloxacin. Several 
models were tested to fit the absorption phase; however, all ab-
sorption models showed an underestimation of the individual 
predicted maximum concentration. Therefore, the model pre-
dicts a slightly lower ciprofloxacin exposure (AUC). This might 
be due to the limited data available during the absorption phase.
In conclusion, ciprofloxacin exposure shows a large difference 
throughout the treatment of pediatric ALL, with about twice 
the exposure during concomitant chemotherapy compared to 
the prednisone prophase. The current prophylactic treatment 
with ciprofloxacin seems to be adequate with limited emer-
gence of resistance and few bacteremia. If the current AUC24/
MIC ratio of 125 is correct, the MIC cutoff of 0.25 mg/L might 
Table 4. Results of Micro-organism Selective Decontamination of 
Digestive Tract
Resistant micro-organisms MIC (mg/L) resistanta No Pat
Escherichia coli ≥ 0.5 14
Pseudomonas aeruginosa ≥ 0.5 3
Klebsiella pneumoniae ≥ 0.5 1
Citrobacter freundii ≥ 0.5 1




During prophylaxis  13.22%
Abbreviation: EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, 
minimal inhibitory concentration.
aAccording to EUCAST reference database 2019.
Figure 5. Concentration time curve for patient with and without ciprofloxacin 
resistant micro-organisms. Pooled concentration time curve of all observed 
ciprofloxacin concentrations. Samples of patients with resistant gram-nega-
tive cultures during treatment are highlighted in red. On the x-axis the time after 
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be too high. The target at an MIC of 0.25 mg/L is achieved in 
only 18% of the patients overall. However, if current prophy-
lactic therapy suffices even with MIC levels of 0.25 mg/L, the 
target AUC24/MIC is higher than necessary. Therapeutic drug 
monitoring might be recommended with increasing MIC levels 
in order to achieve sufficient AUC24/MIC levels or using the 
mutant selection window (see Firsov et al [2015] or Olofsson 
[2006]) [21, 21] to prevent the emergence of resistance and ac-
quire efficacy targets.
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